[Whitepaper] Migraine Treatment and Calcitonin Gene-Related Peptide Inhibitors: A Real-World Electronic Health Record Case Study

Innovative new treatments hold promise of relief to millions suffering with migraine. Three new migraine preventive medications were approved by the FDA in 2018. The question as to how controlled clinical trial results align with the everyday management of migraine remains. Researchers at VeradigmTM used real-world data derived from a large ambulatory database of de-identified medical records to demonstrate how real-world evidence may be leveraged to assess migraine management.


Sponsored by: